We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Partners Genetics Collaborative Study of Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00319904
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : October 19, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
We will collect DNA from 500 rigorously diagnosed patients with schizophrenia to allow us in the future to examine phenotypic subtypes in relation to genetic variants. Phenotypes will include subgroups based on clinical symptoms, medication response, or other biological markers including neuroimaging or pharmacologic challenges.

Condition or disease
Schizophrenia

  Show Detailed Description

Study Design

Study Type : Observational
Actual Enrollment : 451 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Partners Genetics Collaborative Study of Schizophrenia
Study Start Date : March 2001
Primary Completion Date : October 2017
Study Completion Date : October 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. phenotypic subtypes in relation to genetic variants [ Time Frame: Baseline ]
    We will collect DNA from 500 patients with schizophrenia to examine phenotypic subtypes in relation to genetic variants. Phenotypes will include subgroups based on clinical symptoms, medication response, or other biological markers including neuroimaging or pharmacologic challenges.


Biospecimen Retention:   Samples With DNA
DNA is extracted and stored for future anaysis of genes that may be associated with schizophrenia

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adults with Schizophrenia
Criteria

Inclusion Criteria:

Schizophrenia, any subtype Ages 18-70 years Males or females English speaking Ability to complete symptom rating scales and cognitive tests Ability to provide informed consent

Exclusion Criteria:

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00319904


Locations
United States, Massachusetts
Freedom Trail Clinic
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Mental Health (NIMH)
Investigators
Principal Investigator: Daphne J Holt, M.D., PhD Massachusetts General Hospital
More Information

Publications:
Responsible Party: Daphne Holt, Associate Professor of Psychiatry, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00319904     History of Changes
Other Study ID Numbers: 2001-P-000560
First Posted: April 27, 2006    Key Record Dates
Last Update Posted: October 19, 2017
Last Verified: October 2017

Keywords provided by Daphne Holt, Massachusetts General Hospital:
Schizophrenia
DNA

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders